Article

Late Occurrence of Hyperbilirubinemia and Renal Dysfunction During Nilotinib Treatment for an Elderly Chronic Myeloid Leukemia: A Case Report

2021-04-16

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: Compared with the first-generation tyrosine kinase inhibitor (TKI), Nilotinib exhibited potent inhibition for BCR-ABL kinase activity, approved of the first-line and second-line TKI treatment of CML patients. Nilotinib was generally well tolerated with mild hematologic and non-hematologic adverse events. Hyperbilirubinemia, the most common non-hematologic advers...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 47d73b81-fa2e-55ef-b1a7-c26f22f06301
DOI: 10.21203/rs.3.rs-410186/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Late Occurrence of Hyperbilirubinemia and Renal Dysfunction During Nilotinib Treatment for an Elderly Chronic Myeloid Leukemia: A Case ReportDOI 10.21203/rs.3.rs-410186/v1Read

Nilotinib-induced liver injury: A case report.Semantic proximity Read

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.Semantic proximity Read

Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation.Semantic proximity Read

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Semantic proximity Read

Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.Semantic proximity Read

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity Read

Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia.Semantic proximity Read

Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case reportSemantic proximity Read

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.Semantic proximity Read

[Treatment of two chronic myeloid leukemia patients with V299L mutation by using nilotinib].Semantic proximity Read

H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report.Semantic proximity Read

Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.Semantic proximity Read